The Procter Gamble Company

Benjamin Eric Blass

Biswanath De

Michael G Natchus

Michael Philip Clark

John Charles Van Rens

Joshua Spector Tullis

Song Liu

David Edward Portlock

Triazole compounds useful in treating diseases associated with unwanted cytokine activity

The subject invention involves process for making fuctionalized oxazolidinones having structure (1) wherein: (a) R1 and R2 are each independently selected from hydrogen, alkyl, aryl and heterocycle, or R1 and R2 are attached to form a cycloalkyl, aryl or heterocyclic ring; (b) R3 is selected from primary and secondary alkly (&mdash;R6), &mdash;SO &mdash;R4, and &mdash;C(O)NH&mdash;R5; (c) R4 is aryl; and (d) R5 is alkyl or aryl; the process comprising a reaction step carried out in a reaction mixture, wherein an oxazolidinone is reacted with an electrophile selected from R6-Br, R6-I, R4-SO Cl, and R5-NCO; the reaction mixture comprising a non-protic and non-oxidizing solvent and potassium fluoride on alumina; and without the presence of a substantial amount of a strong base in the reaction mixture. The subject invention also involves libraries of functionalized oxazolidinone compounds and their preparation using such processes.

Process for making functionalized oxazolidinone compounds

The subject invention involves compounds having structure (I): wherein each R1 is independently alkyl, aryl, or heterocycle; each R2, R4, R7, and R8 is independently hydrogen or other substituent; A is aryl or heterocycle; and pharmaceutically acceptable forms thereof. The subject invention also involves pharmaceutical compositions containing such compounds, and methods for treating or preventing diseases or disorders using such compounds.

N-(1-phenylethyl)-5-phenyl-imidazole-2-amine compounds, their compositions and uses

Growing community of inventors

Cincinnati, OH, United States of America

Benjamin Eric Blass